B超检查对结核性胸膜炎患者胸腔尿激酶注入疗效评估的分析  

Analysis of efficacy evaluation of B-ultrasound on the patients with tuberculous pleurisy pleural treated by injection of urokinase

作　　者：彭德虎[1] 林兆原[1] 石琳[1] 胡锦兴[1] 罗立全[1] 

机构地区：[1]广州市胸科医院,广州510095

出　　处：《中国防痨杂志》2011年第6期369-371,共3页Chinese Journal of Antituberculosis

摘　　要：目的探讨超声检查对结核性胸膜炎患者胸腔注射尿激酶疗效评估的价值。方法收集2009年1—6月113例结核性胸膜炎的病例资料,对比分析20例胸腔注射尿激酶治疗前后超声检查结果。结果胸腔积液超声改变分为3型,Ⅰ型49例(43.4%),Ⅱ型51例(45.1%),Ⅲ型13例(11.5%)。治疗后,未注射尿激酶组:Ⅰ型胸膜增厚率为12.2%,Ⅱ型为69.4%,Ⅲ型为100%,3组间差异有统计学意义。注射尿激酶组:Ⅱ型胸膜增厚的发生率33.3%,与未注药组(69.4%)比较,差异有统计学意义,Ⅲ型为100%,与未注药组比较差异无统计学意义。结论超声检查对于胸腔注入尿激酶的疗效评估有一定参考价值。Objective To study analysis of efficacy evaluation of B-ultrasound on the patients with tuberculous pleurisy pleural treated by injection of urokinase. Methods 113 cases of patients with tuberculous pleurisy pleural were collected from January to June of 2009.in 20 of whom the results of Ultrasonography was analyzed after and before the treatment by injection of urokinase. Results There are three types of B-mode ultrasonic images in tuberculous pleural effusion： type Ⅰ is 49（43.4%）,type Ⅱ 51（45.1%） and type Ⅲ 13（11.5%）.No injected urokinase into pleural cavity： the incidence rate of pleural thickening was 12.2% in type Ⅰ,69.4% in typeⅡand 100% in type Ⅲ.There were significant differences among them（P0.005）.Injected urokinase into pleural cavity：the rate of pleural thickening was 33.3% in type Ⅱand 69.4% in no injected urokinase,showing that a significant difference was found between them（P0.05）.The incidence rates of pleural thickening were 100% in type Ⅲ both after injected urokinase and no injected urokinase. Conclusions There ar e evaluation of therapeutic effect after injected urokinase.

关 键 词：超声检查 结核 胸膜 尿激酶 

分 类 号：R521.7[医药卫生—内科学]